Lilly reports greater weight loss with EloraTZP, alongside higher discontinuation rates

Eli Lilly announced September 30 that its experimental eloralintide–tirzepatide combination produced greater average weight loss than tirzepatide alone in a Phase 2b trial. The findings advance a strategy of combining peptide therapies that target complementary metabolic pathways, while higher discontinuation rates raise questions about how consistently patients could sustain treatment.

The results were presented at the European Association for the Study of Diabetes meeting in Milan. They remain sponsor-reported findings; the sources reviewed do not establish the combination’s long-term clinical benefits.

What the trial measured

The 48-week, randomized, double-blind study included 367 adults with overweight or obesity and type 2 diabetes. Its primary endpoint compared percentage weight change for combination treatment against placebo. Comparisons with individual medicines and changes in glycated hemoglobin, or A1C, were secondary endpoints.

Lilly’s trial listing identifies the study as NCT06603571. Eligibility extended from ages 18 to 75 and required stable weight before screening. Exclusions included type 1 diabetes and certain serious medical histories, including pancreatitis and recent cardiovascular events. Those selection criteria limit how broadly the findings can be applied, particularly to older or medically complex populations.

The highest tested combination produced a reported average weight reduction of 23.3%, compared with 14.8% for tirzepatide alone. Reported A1C reductions reached 2.9 percentage points with the combination versus 2.4 percentage points with tirzepatide. Reuters independently reported these figures from the announcement and meeting.

Why treatment persistence matters

The headline figures use an efficacy estimand: an analysis estimating outcomes if randomized participants remained on treatment, allowing specified interruptions or modifications. That differs from measuring what everyone actually experiences after starting therapy, including people who stop.

Discontinuations attributed to adverse events ranged from 10.8% to 27.0% across combination groups, compared with 2.9% for tirzepatide and 16.7% for placebo. Gastrointestinal symptoms were the most common adverse events and occurred more frequently with combination treatment than with either medicine alone.

These findings make tolerability a central development question. A large estimated effect under continued treatment does not establish the benefit patients would retain when discontinuation is common. The relatively high placebo discontinuation rate also warrants examination in the complete study report; the headline percentages alone cannot explain why participants stopped.

The biological rationale has earlier roots

Eloralintide mimics amylin, a peptide released alongside insulin after food intake. Amylin participates in appetite regulation, stomach emptying and post-meal glucagon control. Tirzepatide acts through GIP and GLP-1 receptors, providing a different set of metabolic signals.

A peer-reviewed Molecular Metabolism paper published in October 2025 described eloralintide’s receptor activity, animal experiments and an initial randomized human study. That human component involved 48 healthy participants receiving a single administration, with safety and tolerability as its primary objective.

The earlier work supports the rationale for developing the molecule. It cannot establish the safety of prolonged combination treatment in people with diabetes. Likewise, receptor selectivity demonstrated in laboratory assays does not guarantee better tolerability when two medicines are used together.

What remains unresolved

Lilly plans Phase 3 testing of a combined formulation by the end of 2026. The present trial used separate injections, making the next development step relevant to both formulation and treatment persistence.

For healthspan research, the unanswered questions extend beyond weight and glucose measurements: whether benefits endure, whether physical function is maintained, and whether treatment reduces major disease complications. Those outcomes cannot be inferred from this announcement. Larger trials and fuller reporting will be needed to assess the balance between metabolic effects, adverse events and sustained use.